New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:07 EDTRNAProsensa to get additional funding from nonprofit CureDuchenne
Prosensa Holding announced that an affiliate of CureDuchenne, a U.S. national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy, or DMD, will provide Prosensa with up to EUR5M by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of EUR4.5M of the notes is contingent upon specified milestones in the advancement of drisapersen and the company's other exon skipping candidates in Prosensa's DMD portfolio. The funding arrangement will assist the company in progressing the second exon skipping candidate for the treatment of DMD, PRO044, by initiating a Phase II clinical extension study in Europe by the end of 2014 and a placebo-controlled trial in the U.S. in the first half of 2015, which may serve as one of two confirmatory studies to support a potential accelerated approval for drisapersen. It will also support re-dosing efforts for drisapersen clinical trial participants in North America and Europe and facilitate the drug's New Drug Application filing in the U.S. in 2014 along with the development of other Prosensa's other exon skipping compounds, PRO045 and PRO053.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
07:04 EDTRNAProsensa reports Q3 EPS (EUR 0.29) vs. (EUR 0.12) last year
November 14, 2014
16:19 EDTRNAGIMV reports 1.43% passive stake in Prosensa
November 10, 2014
15:53 EDTRNACredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use